The CSF3R T618I mutation as a disease-specific marker of atypical CML post allo-SCT

Bone Marrow Transplantation

Volumn 49, Issue 6, 2014, Pages 843-844

  Langabeer, S E ^a   McCarron, S L ^a   Haslam, K ^a   O'Donovan, M T ^a   Conneally, E ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYTARABINE; DAUNORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; HYDROXYUREA; IMATINIB; TIOGUANINE;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ATYPICAL CHRONIC MYELOID LEUKEMIA; CASE REPORT; CHIMERA; CHRONIC MYELOID LEUKEMIA; CSF3R GENE; DEATH; DONOR LYMPHOCYTE INFUSION; DRUG RESPONSE; ERYTHROCYTE TRANSFUSION; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; LETTER; LEUKOCYTE COUNT; MALE; MIDDLE AGED; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; REDUCED INTENSITY CONDITIONING; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEQUENCE ANALYSIS; SKIN DISEASE; THROMBOCYTE TRANSFUSION; TREATMENT DURATION;

EID: 84902073365     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2014.35     Document Type: Letter

References (10)

1. Vardiman JW, Bennett JM, Bain BJ, Brunning RD, Thiele J. Atypical chronic myeloid leukaemia, BCR-ABL1 negative. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW (eds). WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. International Agency for Research on Cancer: Lyon, France, 2008, pp 80-81.
2. Breccia M, Biondo F, Latagliata R, Carmosino I, Mandelli F, Alimena G. Identification of risk factors in atypical chronic myeloid leukemia. Haematologica 2006; 91: 1566-1568.
3. Koldehoff M, Beelen DW, Trenschel R, Steckel NK, Peceny R, Ditschkowski M et al. Outcome of hematopoietic stem cell transplantation in patients with atypical chronic myeloid leukemia. Bone Marrow Transplant 2004; 34: 1047-1050.
4. Maxson JE, Gotlib J, Pollyea DA, Fleischman AG, Agarwal A, Eide CA et al. Oncogenic CSF3R mutations in chronic neutrophilic leukemia and atypical CML. N Engl J Med 2013; 368: 1781-1790.
5. Piazza R, Valletta S, Winkelman N, Redaelli S, Spinelli R, Pirola A et al. Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. Nat Genet 2013; 45: 18-24.
6. Pardanani A, Lasho TL, Laborde RR, Elliott M, Hanson CA, Knudson CA et al. CSF3R T618I is a highly prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia 2013; 27: 1870-1873.
7. Alchalby H, Badbaran A, Bock O, Fehse B, Bacher U, Zander AR et al. Screening and monitoring of MPL W515L mutation with real-time PCR in patients with myelofibrosis undergoing allogeneic-SCT. Bone Marrow Transplant 2010; 45: 1404-1407.
8. Alchalby H, Badbaran A, Zabelina T, Kobbe G, Hahn J, Wolff D et al. Impact of JAK2 V617F mutation status, allele burden, and clearance after allogeneic stem cell transplantation for myelofibrosis. Blood 2010; 116: 3572-3581.
9. Lange T, Edelmann A, Siebolts U, Krahl R, Nehring C, Jäkel N et al. JAK2 p.V617F allele burden in myeloproliferative neoplasms one month after allogeneic stem cell transplantation significantly predicts outcome and risk of relapse. Haemato-logica 2013; 98: 722-728.
10. Kröger N, Alchalby H, Klyuchnikov E, Badbaran A, Hildebrandt Y, Ayuk F et al. JAK2 V617F-triggered preemptive and salvage adoptive immunotherapy with donor-lymphocyte infusion in patients with myelofibrosis after allogeneic stem cell transplantation. Blood 2009; 113: 1866-1868.